Dechra’s Zygolide adds first generic pergolide option for PPID

Zygolide, Dechra’s new pergolide tablet for horses with pituitary pars intermedia dysfunction, or PPID, has moved from promotion into the market after FDA approval in late 2025 and a public FDA announcement on January 9, 2026. The product is the first FDA-approved generic to Prascend for control of clinical signs associated with equine Cushing’s disease, and Dechra is positioning it around lower cost, peppermint flavoring, and a 360-degree scored 1 mg tablet intended to make dose-splitting easier. FDA records show the approval was granted under ANADA 200-823 based on bioequivalence to Prascend. (fda.gov)

Why it matters: For equine veterinarians, this adds a second FDA-approved pergolide option in a category where long-term adherence, dose adjustment, and budget all shape outcomes. PPID is common in older horses, and Dechra says prevalence rises with age, while FDA documents and product labeling highlight the practical issues clinicians already manage: tablets are dosed to the nearest half tablet, some horses need dose escalation, and inappetence remains a notable adverse effect. A lower-cost generic could improve treatment continuity for some pet parents, but practices will still need to counsel clients on monitoring ACTH and clinical response, handling precautions, and the fact that tablets should not be crushed because of human exposure concerns. (dechra-us.com)

What to watch: Watch for early uptake in equine practice, pricing pressure on the PPID category, and whether easier administration translates into better long-term compliance and monitoring. (dechra-us.com)